• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症的治疗进展。

Treatment update in multiple sclerosis.

机构信息

Concord Repatriation General Hospital, Burwest, Burwood, New South Wales, Australia.

出版信息

Curr Allergy Asthma Rep. 2012 Jun;12(3):246-54. doi: 10.1007/s11882-012-0256-5.

DOI:10.1007/s11882-012-0256-5
PMID:22446992
Abstract

Multiple sclerosis is the most common cause of disability in young people in the Western world. Reduced life expectancy and worsening quality of life due to increasing disability later in the disease course have significant personal and societal costs. Changes in treatment strategies and newly available treatments hope to improve the outlook for our often young patients. This paper details currently available treatments and some that are expected to reach the market shortly.

摘要

多发性硬化症是西方世界年轻人中最常见的致残原因。由于疾病后期残疾的增加,导致预期寿命缩短和生活质量恶化,给个人和社会带来了巨大的代价。治疗策略的改变和新的治疗方法的出现,有望改善我们这些常见的年轻患者的前景。本文详细介绍了目前可用的治疗方法和一些即将上市的治疗方法。

相似文献

1
Treatment update in multiple sclerosis.多发性硬化症的治疗进展。
Curr Allergy Asthma Rep. 2012 Jun;12(3):246-54. doi: 10.1007/s11882-012-0256-5.
2
Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia.对多发性硬化症对预期寿命、质量调整生命年和终生总成本的影响进行建模:来自澳大利亚的证据。
Mult Scler. 2020 Apr;26(4):411-420. doi: 10.1177/1352458519831213. Epub 2019 Feb 26.
3
Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada.多发性硬化症的治疗经历、负担及未满足的需求(TRIBUNE):加拿大MS患者的成本与效用
J Popul Ther Clin Pharmacol. 2012;19(1):e11-25. Epub 2012 Jan 10.
4
Direct and indirect costs of Multiple Sclerosis in Baix Llobregat (Catalonia, Spain), according to disability.根据残疾情况,西班牙加泰罗尼亚地区baix Llobregat的多发性硬化症直接和间接成本
BMC Health Serv Res. 2006 Nov 1;6:143. doi: 10.1186/1472-6963-6-143.
5
The challenge of managing patients with multiple sclerosis.管理多发性硬化症患者的挑战。
Nurs Times. 2004;100(4):42-4.
6
Costs and quality of life of multiple sclerosis in Austria.奥地利多发性硬化症的成本与生活质量
Eur J Health Econ. 2006 Sep;7 Suppl 2:S14-23. doi: 10.1007/s10198-006-0382-x.
7
Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression.澳大利亚原发性进行性多发性硬化症的社会成本,以及一种假设的疾病修正治疗可能延迟疾病进展的经济影响。
J Med Econ. 2021 Jan-Dec;24(1):140-149. doi: 10.1080/13696998.2021.1872585.
8
Costs and quality of life of multiple sclerosis in Switzerland.瑞士多发性硬化症的成本与生活质量
Eur J Health Econ. 2006 Sep;7 Suppl 2:S86-95. doi: 10.1007/s10198-006-0383-9.
9
[The development of multiple sclerosis over the age of 50].
Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(9):21-25. doi: 10.17116/jnevro202312309121.
10
[Quality of life in multiple sclerosis].[多发性硬化症患者的生活质量]
Rev Neurol (Paris). 2009 Mar;165 Suppl 4:S123-8. doi: 10.1016/S0035-3787(09)72123-X.

引用本文的文献

1
Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry.基于登记的药物警戒在多发性硬化症中的机遇与挑战:从多中心 REGIMS 登记研究实施中吸取的经验教训。
Drug Saf. 2021 Jan;44(1):7-15. doi: 10.1007/s40264-020-01007-1. Epub 2020 Oct 23.
2
Treatment Patterns, Healthcare Resource Utilization, and Costs Among Medicare Patients with Multiple Sclerosis in Relation to Disease-Modifying Therapy and Corticosteroid Treatment.医疗保险覆盖的多发性硬化症患者的治疗模式、医疗资源利用及费用与疾病修正治疗和皮质类固醇治疗的关系
Neurol Ther. 2019 Jun;8(1):121-133. doi: 10.1007/s40120-018-0123-y. Epub 2018 Dec 18.
3

本文引用的文献

1
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.口服特立氟胺治疗复发型多发性硬化症的 2 期研究的长期随访:安全性和疗效结果长达 8.5 年。
Mult Scler. 2012 Sep;18(9):1278-89. doi: 10.1177/1352458512436594. Epub 2012 Feb 3.
2
Fingolimod for multiple sclerosis.用于治疗多发性硬化症的芬戈莫德
N Engl J Med. 2012 Jan 26;366(4):339-47. doi: 10.1056/NEJMct1101691.
3
Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis.
多发性硬化症疾病修正疗法属性的患者偏好:基于评分的联合分析的开发与结果
Int J MS Care. 2015 Mar-Apr;17(2):74-82. doi: 10.7224/1537-2073.2013-053.
4
TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic.TWEAK/Fn14 轴靶向治疗:将基础科学发现推向临床。
Front Immunol. 2013 Dec 23;4:473. doi: 10.3389/fimmu.2013.00473.
早期临床特征与长期残疾结局的关系:多发性硬化关键干扰素β-1b 试验的 16 年队列研究(随访)。
J Neurol Neurosurg Psychiatry. 2012 Mar;83(3):282-7. doi: 10.1136/jnnp-2011-301178. Epub 2011 Dec 21.
4
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone.意大利多发性硬化症患者接受米托蒽醌治疗后出现急性髓系白血病。
Neurology. 2011 Nov 22;77(21):1887-95. doi: 10.1212/WNL.0b013e318238ee00. Epub 2011 Nov 9.
5
Abstracts of the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. October 19-22, 2011. Amsterdam, The Netherlands.
Mult Scler. 2011 Oct;17(10 Suppl):S9-524.
6
Oral treatment for multiple sclerosis.多发性硬化的口服治疗。
Lancet Neurol. 2011 Nov;10(11):1026-34. doi: 10.1016/S1474-4422(11)70228-9.
7
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.随机试验口服特立氟胺治疗复发型多发性硬化症。
N Engl J Med. 2011 Oct 6;365(14):1293-303. doi: 10.1056/NEJMoa1014656.
8
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.那他珠单抗治疗多发性硬化症:更新的患者选择和监测建议。
Lancet Neurol. 2011 Aug;10(8):745-58. doi: 10.1016/S1474-4422(11)70149-1.
9
Vascular aspects of multiple sclerosis.多发性硬化的血管方面。
Lancet Neurol. 2011 Jul;10(7):657-66. doi: 10.1016/S1474-4422(11)70105-3.
10
A critical appraisal of treatment decisions in multiple sclerosis--old versus new.多发性硬化症治疗决策的批判性评价——旧与新。
Nat Rev Neurol. 2011 May;7(5):255-62. doi: 10.1038/nrneurol.2011.41. Epub 2011 Apr 5.